Table 2.
Two data sets | Three data sets | ||||||
---|---|---|---|---|---|---|---|
KEGG cancer pathways | U/D | CES | Diff. | FDR | CES | Diff. | FDR |
PPAR signaling * | down | 0.671 | >0.1 | 0.194 | 0.563 | >0.1 | 0.210 |
MAPK signaling ** | down | 0.639 | >0.1 | 0.209 | 0.857 | >0.1 | 0.063 |
ERBB signaling * | up | 0.629 | >0.1 | 0.119 | 0.581 | >0.1 | 0.188 |
Calcium signaling ** | down | 0.925 | >0.1 | 0.051 | 0.694 | >0.1 | 0.153 |
Cytokine-cytokine receptor interaction *** | down | 0.717 | >0.1 | 0.172 | 0.943 | >0.1 | 0.022 |
Cell cycle *** | up | 0.998 | >0.1 | <0.001 | 0.959 | >0.1 | 0.012 |
p53 signaling *** | up | 0.999 | >0.1 | <0.001 | 0.944 | >0.1 | 0.018 |
MTOR signaling * | down | 0.724 | >0.1 | 0.167 | 0.611 | >0.1 | 0.193 |
Apoptosis * | down | ≤ 0.1 | 0.776 | >0.1 | 0.102 | ||
WNT signaling *** | down | ≤ 0.1 | 0.888 | >0.1 | 0.048 | ||
TGF-β signaling | down | ≤ 0.1 | 0.521 | >0.1 | 0.236 | ||
VEGF signaling *** | down | 0.784 | >0.1 | 0.136 | 0.919 | >0.1 | 0.033 |
Focal adhesion *** | up | >0.999 | >0.1 | <0.001 | 0.830 | >0.1 | 0.077 |
ECM receptor interaction *** | up | 0.996 | >0.1 | <0.001 | 0.977 | >0.1 | 0.005 |
Adherens junction * | up | 0.646 | >0.1 | 0.114 | ≤ 0.1 | ||
JAK-STAT signaling *** | down | 0.875 | >0.1 | 0.082 | 0.901 | >0.1 | 0.044 |
Our application results for sixteen KEGG cancer pathways. "Diff" column presents the absolute difference between the CES based on up-regulated differential expression and the CES based on down-regulated differential expression. If "Diff"≤ 0.1, then no further analysis results is presented. Otherwise, the larger CES as well as the related FDR and differential expression direction (up or down) are presented in the "CES", "FDR" and "U/D" columns, respectively. Both application results (an integrative analysis of two data sets and an integrative analysis of three data sets) are presented for the listed pathways. Pathways with symbols *, ** or *** means that FDRs < 0.2, FDRs < 0.1 or FDRs < 0.05 are observed for at least one applications, respectively.